NCT05995418Recruiting
Study on the Health Economic Burden of Alzheimer's Disease in China
The Alzheimer's Disease Burden in China (ABC) Study: a Nationwide Multicentre Cross-sectional and Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
Alzheimer's disease (AD) presents a significant socio-economic challenge globally, with China experiencing a notable rise in its prevalence. This study addresses critical gaps in understanding AD's economic burden and quality of life (QoL) impacts on patients and caregivers in Mainland China.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 9510 (estimated)
- First submitted
- 30 Jul 2023
- Start date
- 1 Jul 2023
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- Alzheimer disease
- NCT number
- NCT05995418
What you commit to
- Study type: Observational
- Planned participants: 9510
- From 1 Jul 2023 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD.
- 2.Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction.
- 4.Participants or their legal representatives sign informed consent. Exclusion criteria
- History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2).
- Presence of mental or neurological developmental delay.
- Presence of other known conditions that may cause cognitive impairment.
- Diagnosis of a disease that prevents completion of cognitive assessments.
- Refusal to sign informed consent at baseline.
Age in the registry: 40 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.